| - Head-to-head study to compare the relative efficacy of Cimzia® (certolizumab pegol) and Humira® (adalimumab) in the treatment of moderate to severe rheumatoid arthritis BRUSSELS, Dec. 21, 2011 /PRNewswire/ -- UCB today announced the start of the EXXELERATE™ study which will evaluate the short- and long-term efficacy of Cimzia® (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira®* (adalimumab) plus MTX in the treatment of moderate to severe rheu...continued UCBJY |
Wednesday, December 21, 2011
UCB Announces Start of the EXXELERATE(tm) Clinical Study in Rheumatoid Arthritis
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment